Expression of immune checkpoints on circulating tumor cells in men with metastatic prostate cancer
Tian Zhang(Duke Medical Center), Andrew J. Armstrong(Duke University), R. Garland Almquist(Duke Medical Center), Elizabeth Bronson(Duke Cancer Institute), Monika Anand(Duke University), Daniel J. George(Duke University), Patrick Healy(Duke University), Daniella Runyambo(Duke Medical Center), Sally Park(Duke Medical Center), Taofik Oyekunle(Duke University), Anika Agarwal(Duke Medical Center), Rengasamy Boominathan(Janssen (United States)), Chandra Rao(Janssen (United States)), Megan McNamara(Duke Medical Center), Kathryn E. Ware(Duke University), Jason A. Somarelli(Duke Medical Center)
Cited by 49
Related Papers
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k
Circulating Tumor Cells from Patients with Advanced Prostate and Breast Cancer Display Both Epithelial and Mesenchymal Markers
|Molecular Cancer Research|2011|650
Plastic pollution solutions: emerging technologies to prevent and collect marine plastic pollution
|Environment International|2020|440